First Horizon Advisors Inc. Buys 608 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Horizon Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,515 shares of the biopharmaceutical company’s stock after buying an additional 608 shares during the quarter. First Horizon Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,748,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fortitude Family Office LLC bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $40,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on REGN shares. Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Truist Financial reiterated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, Barclays lifted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Insiders Place Their Bets

In other news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 10,095 shares of company stock worth $9,664,476 in the last 90 days. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $38.76 during trading hours on Thursday, reaching $942.24. 533,717 shares of the stock traded hands, compared to its average volume of 492,750. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company’s 50-day moving average price is $944.78 and its two-hundred day moving average price is $895.25. The company has a market cap of $103.42 billion, a P/E ratio of 26.00, a price-to-earnings-growth ratio of 2.55 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the company earned $10.96 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.